Osivelotor - Global Blood Therapeutics/Pfizer
Alternative Names: GBT-021601; GBT-601; PF-07940367Latest Information Update: 25 Jul 2024
At a glance
- Originator Global Blood Therapeutics; Pfizer
- Class Antianaemics; Small molecules; Urologics
- Mechanism of Action Sickle haemoglobin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Sickle cell anaemia
- Phase I Renal failure
Most Recent Events
- 25 Jul 2024 Pfizer plans phase I trial in healthy volunteers (PO) (EudraCT2024-511410-20-00) (NCT06507904)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (PO, Capsule)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (PO, Tablet)